Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WGb-0302 Injection in Recurrent and Refractory Hematological Malignancies
NCT07362732Phase 1Not yet recruiting
- Sponsor
- Sichuan University
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
01
Overview
Phase 1, open-label trial of WGb-0302 in multiple myeloma (MM) (2 arms), sponsored by Sichuan University. Primary endpoints: Incidence of Dose Limiting Toxicity at 90 days, Maximum Tolerated Dose at 2 years and 1 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
WGb-0302
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07362732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07362732.